Results for tag: "Vertex Triple Combination"

The Vertex Triple Combination market is a subset of the respiratory drug market, focusing on treatments for cystic fibrosis (CF). CF is a genetic disorder that affects the lungs and digestive system, and is caused by a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Vertex Triple Combination therapies are a combination of three drugs that target the underlying cause of CF, and are designed to improve lung function and reduce the frequency of exacerbations. These therapies are typically administered orally, and are often used in combination with other treatments such as antibiotics and airway clearance techniques. The Vertex Triple Combination market is a rapidly growing segment of the respiratory drug market, with a number of companies developing and marketing these therapies. Some of the major players in this market include Vertex Pharmaceuticals, Gilead Sciences, Novartis, and AstraZeneca. Show Less Read more